Lipella Pharmaceuticals Inc. (LIPO)

Lipella Pharmaceuticals will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Cap n/a
Revenue (ttm) 207,998
Net Income (ttm) -1.99M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About LIPO

Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. This strategy allows us to expedite, protect, and monetize our product candidates. Additionally, we maintain a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. We believe that this focus can potentially help reduce the cost, time and risk associated... [Read more...]

Industry Health Care
Founded 2005
CEO Jonathan Kaufman
Employees 4
Stock Exchange NASDAQ
Ticker Symbol LIPO
Full Company Profile

Financial Performance

In 2021, LIPO's revenue was $259,347, a decrease of -73.03% compared to the previous year's $961,683. Losses were -$1.87 million, 2,925.6% more than in 2020.

Financial Statements


Lipella Pharmaceuticals IPO Registration Document (S-1)

Lipella Pharmaceuticals has filed to go public with an IPO on the NASDAQ.